NO20060955L - Farmasoytisk sammensetning som er nyttig til stamcellemobilisering - Google Patents

Farmasoytisk sammensetning som er nyttig til stamcellemobilisering

Info

Publication number
NO20060955L
NO20060955L NO20060955A NO20060955A NO20060955L NO 20060955 L NO20060955 L NO 20060955L NO 20060955 A NO20060955 A NO 20060955A NO 20060955 A NO20060955 A NO 20060955A NO 20060955 L NO20060955 L NO 20060955L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
stem cell
composition useful
cell mobilization
mobilization
Prior art date
Application number
NO20060955A
Other languages
English (en)
Inventor
Francesco Colotta
Alessandro Massimo Gianni
Carmelo Carlo-Stella
Original Assignee
Dompe Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dompe Spa filed Critical Dompe Spa
Publication of NO20060955L publication Critical patent/NO20060955L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Det er beskrevet et kombinert farmasøytisk preparat som irmeholder G-CSF og PIGF som aktive stoffer, som er nyttig for mobilisering av blodstamceller i en pasient eller individ med behov derav.
NO20060955A 2003-07-29 2006-02-27 Farmasoytisk sammensetning som er nyttig til stamcellemobilisering NO20060955L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03017174 2003-07-29
PCT/EP2004/008245 WO2005014023A1 (en) 2003-07-29 2004-07-23 Pharmaceutical combination of g-csf and plgf useful for blood stem cell

Publications (1)

Publication Number Publication Date
NO20060955L true NO20060955L (no) 2006-02-27

Family

ID=34130041

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060955A NO20060955L (no) 2003-07-29 2006-02-27 Farmasoytisk sammensetning som er nyttig til stamcellemobilisering

Country Status (21)

Country Link
US (1) US20070036747A1 (no)
EP (1) EP1660115B1 (no)
JP (1) JP4855253B2 (no)
KR (1) KR101192136B1 (no)
CN (1) CN100534528C (no)
AT (1) ATE513555T1 (no)
AU (1) AU2004262909B2 (no)
BR (1) BRPI0412989A (no)
CA (1) CA2526244C (no)
DK (1) DK1660115T3 (no)
ES (1) ES2369487T3 (no)
IL (1) IL173369A (no)
MX (1) MXPA06000017A (no)
NO (1) NO20060955L (no)
NZ (1) NZ543612A (no)
PL (1) PL1660115T3 (no)
PT (1) PT1660115E (no)
RU (1) RU2351357C2 (no)
SI (1) SI1660115T1 (no)
WO (1) WO2005014023A1 (no)
ZA (1) ZA200509361B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006093993A1 (en) 2005-03-02 2006-09-08 University Of Maryland Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en) 2008-03-25 2011-05-19 University Of Maryland, Baltimore Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
WO2009129208A2 (en) 2008-04-14 2009-10-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress reponse
GB2479693B (en) 2009-02-05 2014-04-09 Tokai Pharmaceuticals Inc Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
BRPI1008745A2 (pt) 2009-02-05 2019-09-17 Tokai Pharmaceuticals Inc pró-fármacos de inibidores esteroidais de cyp17/antiandrogênios
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
CN105431521A (zh) 2013-02-28 2016-03-23 哈佛学院校长同事会 用于动员干细胞的方法和组合物
EP2968370A4 (en) 2013-03-14 2016-09-21 Univ Maryland AGENT FOR ANDROGEN RECEPTOR DOWNWARD CONTROL AND USES THEREOF
AU2014306698A1 (en) 2013-08-12 2016-01-28 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
LT6161B (lt) 2013-09-27 2015-06-25 Uab Profarma Granuliocitų kolonijas stimuliuojančio faktoriaus sulieti baltymai su kitais augimo faktoriais, optimaliai su kamieninių ląstelių faktoriumi, ir jų gavimo būdas
CN114891746A (zh) * 2021-12-21 2022-08-12 青岛今墨堂生物技术有限公司 一种犬全血造血干细胞的制备方法
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2024081820A1 (en) 2022-10-13 2024-04-18 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773252A (en) * 1995-06-05 1998-06-30 Human Genome Sciences, Inc. Fibroblast growth factor 15
DE19549232C2 (de) * 1995-12-20 1998-05-20 Boehringer Mannheim Gmbh Verwendung von G-CSF in Kombination mit einem Chemotherapeutikum bei der Behandlung von Erkrankungen, die eine periphere Stammzelltransplantation erfordern
US7105168B1 (en) * 2002-06-04 2006-09-12 D. Collen Research Foundation Vzw Method of improving ischemic muscle function by administering placental growth factor
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
WO2004070018A2 (en) * 2003-02-04 2004-08-19 Ludwig Institute For Cancer Research Vegf-b and pdgf modulation of stem cells

Also Published As

Publication number Publication date
ATE513555T1 (de) 2011-07-15
DK1660115T3 (da) 2011-10-10
RU2351357C2 (ru) 2009-04-10
EP1660115B1 (en) 2011-06-22
EP1660115A1 (en) 2006-05-31
PL1660115T3 (pl) 2011-11-30
JP2007500157A (ja) 2007-01-11
SI1660115T1 (sl) 2011-10-28
AU2004262909B2 (en) 2010-07-01
RU2006106228A (ru) 2007-09-10
BRPI0412989A (pt) 2006-10-03
KR101192136B1 (ko) 2012-10-16
PT1660115E (pt) 2011-08-24
ES2369487T3 (es) 2011-12-01
JP4855253B2 (ja) 2012-01-18
MXPA06000017A (es) 2006-03-21
CN1826134A (zh) 2006-08-30
KR20060079753A (ko) 2006-07-06
WO2005014023A1 (en) 2005-02-17
AU2004262909A1 (en) 2005-02-17
IL173369A (en) 2010-12-30
US20070036747A1 (en) 2007-02-15
ZA200509361B (en) 2007-03-28
NZ543612A (en) 2008-03-28
CA2526244A1 (en) 2005-02-17
IL173369A0 (en) 2006-06-11
CN100534528C (zh) 2009-09-02
CA2526244C (en) 2012-03-20

Similar Documents

Publication Publication Date Title
NO20060955L (no) Farmasoytisk sammensetning som er nyttig til stamcellemobilisering
NO20064584L (no) Tetrahydropyridoindolderivater
NO20064347L (no) Substituerte 1,2,3,4-tetrahydroisokinolinderivater
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
NO20062709L (no) Stamceller som er egnet for transplantasjon, fremstilling derav og farmasoytiske preperater omfattende nevnte stamceller
BRPI0510428A (pt) composições tópicas de metadona e processos para utilização das mesmas
DK1682446T3 (da) Lithiummetalphosphater, fremgangsmåde til deres fremstilling og anvendelse som elektrodematerialer
BRPI0409133B8 (pt) preparações farmacêuticas estavéis compreendendo metilnaltrexona
NO20063430L (no) Generelt lineaer, brusende oral fentanyl doseringsform, og metoder for administrering
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
NO20050795L (no) Forbindelser, blandinger og fremgangsmater for utnyttelse av samme
BRPI0515332A (pt) composições e seus usos para deficiências das enzimas lisossÈmicas
NO20054765L (no) Nye probiotiske sammensetninger og fremgangsmater for anvendelse derav
DK1654253T3 (da) Substituerede 3-pyrrolidinindolderivater
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
DK1498039T3 (da) Vitale cellepræparater, som indeholder mælkesyrebakterie som aktivt stof, og mælkesyrebakterieholdige fødevareprodukter
MXPA05012319A (es) Suministro de compuestos con celulas sanguineas rehidratadas.
NO20072290L (no) Organiske forbindelser.
EP2177531A3 (en) Cell permeable peptide
FR2850576B1 (fr) Composition comprenant un melange de principes actifs, et procede de preparation
NO20042158L (no) Substituert 4-fenyl-tetrahydroisokinoliner, fremgangsmate for fremstilling derav, anvendelse derav som medikamenter, i tillegg til medikamenter inneholdende samme
NO20065898L (no) 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner
DK1655030T3 (da) Benzothiadiazinforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger, som indeholder disse
FR2883184B1 (fr) Composition de spirulines riche en principes actifs, procede d'obtention et utilisation
EA200700067A1 (ru) Фармацевтическая композиция, содержащая производные пиперазина

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application